|
FDA Predictive Drug Safety Models, Biomarkers Could Guide Industry
The FDA plans to develop predictive models for preclinical drug safety and efficacy and identify more biomarkers to predict responses to these drugs — knowledge that could influence drugmakers’ development and marketing decisions.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives